1. Primary Aim: To evaluate the efficacy of atomoxetine in reducing the frequency of primary nocturnal enuresis episodes in children with ADHD. 2. Secondary Aim: To determine if improvements in attention symptoms correlate with reductions in nocturnal enuresis episodes.
Children aged 6-12 years diagnosed with ADHD per Conners-48 scale. Children experiencing primary nocturnal enuresis.
Secondary causes of enuresis (e.g., urinary tract infections, diabetes). Use of other enuresis treatments. Known contraindications to atomoxetine.
Parallel
Atomoxetine
DrugAtomoxetine, 0.5-1.2 mg/kg/day, administered in the evening for six months.
Placebo
DrugPlacebo identical in form and dosing schedule for six months.
Frequency of nocturnal enuresis episodes, recorded by parents in a nightly log.
* Baseline data: enuresis frequency. * Follow-up assessments at 1, 3, and 6 months: Parent-maintained logs of enuresis episodes.
ADHD symptoms, assessed using Conners-48 scores at baseline, 1, 3, and 6 months
* Baseline data: demographic details, ADHD severity (Conners-48), * Follow-up assessments at 1, 3, and 6 months: * Conners-48 scores to monitor ADHD symptom changes.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
